Compare DexCom, Inc. (DXCM) vs Tesla, Inc. (TSLA) Price & Performance

DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.

The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.

Tesla (TSLA) trades at $332.71, up 0.56% on the day, as the stock shows mixed signals with bearish technical indicators but recent positive earnings beats. The company faces declining profit margins (net income margin of 3.67% in 2025) despite steady revenue near $95B, while valuation ratios remain elevated with a P/E of 308. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model.

Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include competitive pressures and high valuation. Analyst consensus price target of $393.87 suggests 18% upside, though technical weakness and earnings volatility warrant caution. Investment opportunity hinges on Tesla's pivot beyond automotive into robotics and energy.